Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy
NCT ID: NCT05987397
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
2700 participants
INTERVENTIONAL
2023-07-05
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.
NCT02526225
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
NCT03296618
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
NCT01958957
Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
NCT06861426
Dyslipidemia Management in Chinese Post Stroke Patients
NCT01897883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Idebenone short-term treatment group
The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
idebenone 30 mg for 14 days
The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
Group B: Idebenone long-term treatment group
The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
idebenone 30 mg for 3 months
The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
idebenone 30 mg for 14 days
The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
idebenone 30 mg for 3 months
The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to cooperate with the inspection;
* Sign the informed consent form.
Exclusion Criteria
* A history of serious comorbidities that may lead to seizures (including malignant tumors, specific autoimmune diseases, severe electrolyte abnormalities, end-stage renal disease, and severe head trauma);
* Secondary stroke caused by head trauma or surgery;
* Other patients that the researchers think need to be excluded.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Feng, MD, PhD
Associate Professor Vice Director of Neurology Teaching and Research Office
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xiangya Hospital, Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202306124
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.